Graham Taylor - University of Melbourne - Maximising the advantages and addressing the limitation of clonal sequencing in diagnostics
Question: Should genome sequencing of multiple oncogenes surplant BRAF V600 mutation testing by an FDA approved test? Answer: Yes Jeffrey A Sosman MD Ingram.
